leadf
logo-loader
viewTonix Pharmaceuticals
(
NASDAQ:TNXP
)

Tonix Pharma CEO discusses Phase 3 RALLY study results and intent to acquire new R&D facility

Tonix Pharmaceuticals (NASDAQ:TNXP) Holding Corp. (NASDAQ: TNXP) CEO Dr. Seth Lederman tells Proactive why the clinical-stage biopharmaceutical company had decided to stop enrollment in its Phase 3 RALLY study of TNX-102 SL to treat fibromyalgia.

In addition, Dr. Lederman discussed the group's intent to acquire a 48,000 square foot infectious disease R&D Facility in Frederick, Maryland, to help the expand its infectious disease pipeline.

Quick facts: Tonix Pharmaceuticals

Follow
NASDAQ:TNXP

Price: 0.6063 USD

Market Cap: $216.77 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Tonix Pharmaceuticals to develop therapeutic to treat Long COVID Syndrome

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Dr Seth Lederman talks to Proactive about how the clinical-stage biopharmaceutical company plans to develop TNX-102 SL as a potential treatment for Long COVID Syndrome, known officially as Post-Acute Sequelae of COVID-19. Dr Lederman says...

on 07/15/2021

2 min read